Quadruple Misfolded Proteins in Older Adults

- Posted by admin in English

In this cohort study, Shama Karanth and colleagues from University of Kentucky, Lexington, investigated quadruple misfolded proteins and other proteinopathy combinations in a cohort of 375 deceased individuals with autopsy data in the University of Kentucky Alzheimer Disease Center (UK-ADC).

At least 3 proteinopathies were observed in 50% of brains.

In addition, quadruple misfolded proteins were associated with severe cognitive impairment at least 12 years before death.

Participants with 3 proteinopathies tended to have poorer global cognition earlier than with the presence of only tau and Aβ and were likely to have higher Braak stages.

Previous studies have reported cognitive decline associated with the presence of mixed pathologies, with study to study differences in methods and proteinopathies, the assessment and inclusion of cerebrovascular pathologies, and hippocampal sclerosis. In the present sample, as in other community based cohorts, FTLD in old age was rare (with an estimated incidence of 8.9 of 100 000 in individuals aged 60 to 69 years; no incidence data are available for older age groups) and was not found in brains of individuals who began follow up with normal cognition.

Individuals with FTLD-TDP-43 with data in the UK-ADC Brain Bank were recruited from a dementia clinic. The scientists excluded 6 individuals with FTLD-TDP-43 in the study; none had the quadruple misfolded proteins phenotype. No discernible overlap in any FTLD feature was observed in these individuals other than presence of TDP-43 proteinopathy, which is now detected in many different neurological diseases outside of the amyotrophic lateral sclerosis–FTLD spectrum.

Cognitive impairment was associated with quadruple misfolded proteins at autopsy, with 89.1% of participants developing dementia and some experiencing profound impairment up to 12 years before death. This finding suggests that quadruple misfolded proteins occur before end stage Alzheimer disease neuropathological change (ie, before high Braak stage).

Consistent with this hypothesis, the mild cognitive impairment to dementia transition was, on average, fastest in the quadruple misfolded proteins group. Estimation of the group cognitive trajectories was aided by the relatively long followup (mean duration of 10.4 years).

These data provide the basis for a novel hypothesis that quadruple misfolded proteins have a more aggressive phenotype from the early stages of the disease rather than accruing additional pathologies only after Alzheimer disease neuropathological change has progressed to high levels. About 10% of these participants died with normal cognition, and previous research has shown quadruple misfolded proteins were present in persons with apparently normal cognition. In the present study, all individuals with quadruple misfolded proteins who had normal cognition at the last visit before death had lower Braak NFT stages (I to III), had no APOEε4 allele, and were predominantly male (4 of 5 participants).

These individuals may represent an early stage of quadruple misfolded proteins, but there are complexities: clinical presentation of proteinopathy combinations may be cohort specific and depend on other currently unknown factors. Older cohorts that survive into advanced old age, like those in the UK-ADC study, may be more likely to experience multiple proteinopathies than younger cohorts. As previously described, APOE appeared to be associated with multiple proteinopathies in this study, particularly those proteinopathy combinations including Aβ plaques. Carriers of APOEε allele not only had increased odds of tau and Aβ, an expected result, but also had higher odds of tau, Aβ, and αsynuclein; tau, Aβ, and TDP-43; and quadruple misfolded proteins.

Unlike previous studies, this study did not find evidence that the ε4 allele was associated with tau or TDP-43 in the absence of Aβ, but the sample size was relatively small. The temporality of protein misfolding may play a clinically important and differentiating role in disease progression.

Autopsy data, although cross-sectional by nature, are compatible with the hypothesis that Aβ aggregates precede, and perhaps stimulate or exacerbate, the widespread misfolding of tau, TDP-43, and α-synuclein. These results suggest that TDP-43 pathology may be associated with poor global cognition.

The presence of multiple proteinopathies, particularly the quadruple misfolded proteins phenotype, appeared to have been associated with the cognitive decline in deceased individuals who participated in a longitudinal community based study at the UK-ADC.

These observations have potentially significant implications for clinical practice and public health, given that strategies to prevent or manage AD dementia may be complicated by the unrecognized presence of multiple additional neuropathologies.

Two epigenetic regulators interfere with healthy aging

- Posted by admin in English

It has long been assumed that lifespan and health are strongly correlated, but although there has been an overall increase in human life expectancy in recent decades, it is too often accompanied by deterioration of health.

A new study published on February 26 in Nature shows the influence of two epigenetic regulators on aging. Scientists led by Jie Yuan from the Chinese Academy of Sciences in Shanghai have studied the BAZ-2 and SET-6 proteins in Caenorhabditis elegans worms, which are orthologs of the human proteins BAZ2B and EHMT1.

Through genome-wide RNA-interference-based screening of genes that regulate behavioral deterioration in aging C. elegans, the researchers identified 59 genes as potential health modulators during aging. Essentially the proteins expressed by these genes, read and write epigenetic signals.

Among these modulators, they found that a neuronal epigenetic reader, BAZ-2, and a neuronal histone SET-6, accelerate the deterioration of the behavior of C. elegans by reducing the mitochondrial function, and repressing the expression of the encoded mitochondrial proteins. in the cell nucleus.

The researchers found that the levels of the two proteins increase with age in C. elegans and mice, which in turn attenuates the expression of genes involved in mitochondrial function.

BAZ-2 and SET-6 are complementary epigenetic mechanisms. SET-6 is an "epigenetic writer" and BAZ-2 is an "epigenetic reader" which recognizes modified histones and recruits transcriptional regulators.

Histones are proteins located in the nucleus of eukaryotic cells. They are the main protein components of chromosomes. They are closely associated with DNA and allow their compaction, but they also modify the expression of proteins by various epigenetic mechanisms known as the "histone code".

enter image description here Source Wikipedia.

How do BAZ-2 and SET-6 accelerate aging? The researchers found that the two proteins bind together to the promoter regions of more than 2,000 genes, and decrease their expression via methylation of histones. Among these target genes are many mitochondrial genes encoded nuclear. By suppressing the expression of these genes, BAZ-2 and SET-6 reduce oxygen consumption and ATP production, and decrease the critical stress responses that maintain mitochondrial proteostasis. The resulting metabolic slowdown discourages the worms from assimilating their food and they mate less.

This mechanism is conserved in the neurons of cultured mice and human cells. What about the orthologs of these epigenetic proteins in humans? A review of the databases shows that expression by human orthologs of the two proteins mentioned above, BAZ2B and EHMT1, increases with age and is positively correlated with the progression of Alzheimer's disease. Researchers have verified that ablation of BAZ-2 mouse ortholog Baz2b attenuates age-dependent body weight gain and prevents cognitive decline in aging mice.

enter image description here While wild-type mice grew fat with age, animals lacking both copies of the epigenetic reader Baz2b stayed trim, indicating improved mitochondrial function. [Yuan et al., Nature, 2020.]

However, it must be asked whether BAZ-2 and SET-6 would rather mediate age-related physiological adaptation, rather than the agents of aging itself. Indeed their action could reflect a mechanism of adaptation to a progressively more hostile biological environment.

Old Article 5

- Posted by system in English

Old Article 4

- Posted by system in English

Old Article 3

- Posted by system in English

Old Article 2

- Posted by system in English

Old Article 1

- Posted by system in English

Significance of the Topic: The topic of platform trials for intracerebral hemorrhage (ICH) is significant due to the limited understanding of effective treatments for this condition. ICH is a life-threatening condition that requires immediate medical attention and poses a substantial burden on healthcare systems worldwide. The development of efficient trial designs like platform trials can accelerate the discovery of new treatments and improve patient outcomes.

Importance: The importance of this study lies in its potential to inform the design of future platform trials for ICH. The results can help researchers and clinicians identify the most critical factors that influence recruitment and ensure the successful implementation of such trials. This is crucial for advancing our knowledge of effective treatments for ICH, which is a critical unmet medical need.

Timeliness: The study's timeliness is highlighted by the ongoing efforts to improve stroke care and the growing interest in platform trials as a efficient trial design. The study's findings can inform the development of platform trials for ICH, which is a critical aspect of the field.

Relevance: The study's relevance lies in its focus on the views of clinicians actively involved in stroke research. Their perspectives are essential for ensuring the successful implementation of platform trials and ensuring that the trials are responsive to the needs of patients and clinicians.

Analysis of the Text: The study used a UK-wide online survey of clinicians actively involved in stroke research to investigate their views on recruitment to a future platform trial for ICH. The survey collected quantitative and qualitative data, which were analyzed using descriptive statistics and content analysis, respectively.

Relationship between Items: The study's findings on the modifiable factors influencing recruitment to a platform trial for ICH are closely related to the study's purpose and objectives. The results provide insights into the factors that clinicians perceive as facilitators or barriers to recruitment, which can inform the design of future platform trials.

Usefulness of the Text for Disease Management or Drug Discovery: The study's findings can contribute to the development of efficient trial designs for ICH, which can accelerate the discovery of new treatments. However, the study's results should be considered alongside other factors, such as the current state of the art in ICH treatment, the availability of resources, and the potential risks and benefits of new treatments.

Original Information beyond the Obvious: The study's findings provide original information by highlighting the importance of clinician preferences for specific treatments as a barrier to recruitment and the need for adequate staffing, local research culture and capacity, research governance and delivery, and training as essential infrastructure for successful platform trials.

Comparison with the State of Art: The study's findings build upon existing knowledge of platform trials and ICH treatment. The results are consistent with the importance of clinician involvement in trial design and the need for adequate infrastructure to support successful implementation. However, the study's focus on the views of clinicians and the use of a UK-wide online survey provides new insights into the factors that influence recruitment to platform trials.

In summary, the study provides valuable insights into the views of clinicians involved in stroke research on recruitment to a future platform trial for ICH. The findings can inform the design of efficient trial designs for ICH and contribute to the development of effective treatments for this condition.

Read the original article on medRxiv

Significance of the Topic

The topic of this text revolves around understanding the molecular mechanisms underlying the genetic risks associated with Alzheimer's disease (Alzheimer's disease) conferred by the Apolipoprotein E (APOE) gene. Specifically, it explores the role of the 4 and 2 alleles of the APOE gene in modulating Alzheimer's disease pathology. The significance of this topic lies in its potential to shed light on the underlying biology of Alzheimer's disease, a complex and multifactorial disease.

Importance

Alzheimer's disease is a devastating and debilitating neurodegenerative disorder that affects millions of people worldwide. Understanding the genetic and molecular mechanisms underlying Alzheimer's disease is crucial for developing effective therapeutic strategies and preventing or slowing disease progression. The APOE gene has been associated with Alzheimer's disease risk, with the 4 allele being a well-established risk factor.

However, the underlying molecular mechanisms remain poorly characterized, making this research area highly important and timely.

Timeliness

The text is timely as it addresses a critical knowledge gap in the field of Alzheimer's disease research. Recent advances in proteomics and genomics have enabled researchers to systematically profile APOE-associated proteomic alterations in human samples, providing new insights into the molecular mechanisms underlying Alzheimer's disease. The text leverages these advances to investigate the role of the APOE 4 and 2 alleles in Alzheimer's disease pathology, making it a timely contribution to the field.

Relevance

The text has significant relevance to Alzheimer's disease research, as it provides novel insights into the molecular mechanisms underlying APOE-driven Alzheimer's disease pathology. The findings have implications for the development of therapeutic strategies for early intervention and potentially for the identification of new targets for Alzheimer's disease treatment.

Furthermore, the text highlights the importance of considering the APOE 4 and 2 alleles as distinct risk factors for Alzheimer's disease, rather than just focusing on the 4 allele.

Analysis of the Text

The text presents a comprehensive analysis of APOE-associated proteomic alterations across five cohorts, using a range of proteomics platforms and samples, including plasma and cerebrospinal fluid (cerebrospinal fluid). The study uses systematic profiling to identify a comprehensive APOE-protein network and applies mediation modeling to classify genotype-related signals as upstream mediators, downstream consequences, or APOE-specific changes. The text then leverages cerebrospinal fluid beta-amyloid (A ) biomarker data to improve temporal resolution and isolate early, A -independent proteomic programs.

The findings of the text are significant, as they provide novel insights into the molecular mechanisms underlying APOE-driven Alzheimer's disease pathology. The study identifies allele-specific, temporally structured proteomic signatures that precede Alzheimer's disease pathology, offering potential therapeutic targets for early intervention. The text highlights the importance of considering the APOE 4 and 2 alleles as distinct risk factors for Alzheimer's disease and underscores the challenges in reproducibility associated with proteomics studies.

Usefulness for Disease Management and Drug Discovery

The text provides valuable insights for Alzheimer's disease disease management and drug discovery, as it highlights the potential therapeutic targets for early intervention. The identification of allele-specific, temporally structured proteomic signatures offers a new perspective on Alzheimer's disease pathology and provides a starting point for the development of novel therapeutic strategies. The text also underscores the importance of considering individual variability in APOE genotype as a critical factor in Alzheimer's disease risk, which may inform personalized medicine approaches.

Original Information Beyond the Obvious

While the text presents novel insights into the molecular mechanisms underlying APOE-driven Alzheimer's disease pathology, it does not break new ground in terms of fundamental understanding.

However, the systematic profiling and mediation modeling approaches used in the study provide a comprehensive and nuanced understanding of APOE-associated proteomic alterations, which is a significant advance in the field. The text highlights the challenges associated with reproducibility in proteomics studies, emphasizing the need for careful consideration of sample size, platform choice, and data analysis methods.

Overall, the text provides a comprehensive and insightful analysis of APOE-associated proteomic alterations in human samples, highlighting the importance of considering individual variability in APOE genotype as a critical factor in Alzheimer's disease risk. The findings offer novel insights into the molecular mechanisms underlying APOE-driven Alzheimer's disease pathology and provide potential therapeutic targets for early intervention.

Read the original article on medRxiv

ObjectivesTo characterize the survival of individuals with pathogenic PRNP variants -- including to estimate annual hazards, to judge the accuracy of previously reported survival data, and to evaluate the utility of public record searches in determining vital status.

MethodsIn this single center cohort study, we gathered data on individuals who received positive antemortem PRNP genetic tests at the U.S. National Prion Disease Pathology Surveillance Center (NPDPSC). Genetic test results and autopsy status were queried from the NPDPSC database, and public record searches were conducted using online tools.

Results404 individuals received positive genetic test results. Of 206 cases symptomatic at the time of genetic testing, 188 are likely now deceased based on typical disease duration for their genetic variants. Combined autopsy and public record searches in combination confirmed 174 of these deaths, for an estimated sensitivity of 92.6%. Of 111 autopsied individuals, evidence of death was found in public record searches for 109, a sensitivity of 98.2%. Of 198 individuals who were asymptomatic at the time of testing, 32 since died of definite or possible prion disease. Among 20 of these who underwent autopsy, public record searches confirmed deaths of 18, for a sensitivity of 90%. Among 99 E200K individuals over 936 person-years of follow-up, 18 deaths were observed, significantly fewer than 27.4 expected according to life tables based on retrospective data. The age-dependent penetrance of E200K calculated from these longitudinal data was significantly lower than that from retrospective data, with 69% penetrance by age 80 and a median age at death of 75. No significant difference was found for D178N, which appears highly penetrant, though the median age at death was numerically higher than seen in retrospective data. V210I was associated with just 2 deaths, both after age 90, consistent with minimal penetrance.

DiscussionThese data support the accuracy of penetrance classifications for PRNP variants reported based on retrospective data, but may suggest an age of onset distribution shifted slightly later than that calculated retrospectively. Autopsy data and public death records in combination were sensitive and concordant, but additional prospective data should be gathered to support future preventive trials.

Read the original article on medRxiv


Please, help us continue to provide valuable information: